Malabsorption syndrome is the poor absorption of fat, vitamins, carbohydrate, protein, and other nutrients from the intestinal tract into the bloodstream. The possible major causes of malabsorption syndrome are prolonged use of antibiotics, Celiac disease, Cystic fibrosis, Crohn’s disease, lactose intolerance, parasitic diseases, diseases of the gallbladder or liver, and intestinal inflammation.
It is noted that rising cases of causative diseases such as celiac disease, and others is the key factor driving the malabsorption syndrome market. Celiac disease is a serious autoimmune disorder, and is estimated to affect 1 in 100 people worldwide, suggested by Celiac Disease Foundation.
Reqeust for Reports Sample @ https://www.marketresearchfuture.com/sample_request/5460
Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the global malabsorption syndrome market.
Despite these drivers, there are some issues associated with malabsorption syndrome market. The side effects of drugs and other therapeutic agents, infections, lack of awareness in the developing countries, and poor healthcare system in low and middle-income countries, may hinder the growth of the market.
It is estimated that the malabsorption syndrome market is expected to grow at a CAGR of 11.0% during the forecast period of 2017-2023.
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Government Research Institute
- Academic Institutes and Universities
- Research Methodology
The global malabsorption syndrome market is segmented on the basis of diagnosis, causative diseases, treatment, and end user.
On the basis of the diagnosis, the market is classified as hematologic tests, imaging studies, and other tests. The imaging studies segment is classified as CT scan, magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatogram (ERCP), and abdominal X-ray. The other tests segment is classified as test of fat malabsorption, D-xylose test, tests of carbohydrate absorption, test of bile salt absorption, schilling test, and C-D-xylose breath test.
On the basis of the causative diseases, the market is classified as lactose intolerance, cystic fibrosis, Whipple’s disease, parasitic diseases, tropical sprue, intestinal disorders, and others. The Intestinal disorders segment is further classified as Celiac disease, and others.
On the basis of the treatment, the market is classified as nutritional supplements, gluten-free diet, protease and lipase supplements, antibiotics, antidiarrheal agents, anti-inflammatory drugs, and others.
On the basis of the end user, the market is segmented into pharmaceutical companies, Hospitals, Nutrition Clinics, Academic and Research Institutes, and others.
The Americas dominate the malabsorption syndrome market owing to the rising cases of causative diseases such as lactose intolerance, diarrhea, cystic fibrosis, and others, and high healthcare expenditure. Children and adults with cystic fibrosis are at risk for low bone density, and related complications due to malabsorption of certain nutrients. According to the Cystic Fibrosis Foundation Patient Registry, more than 30,000 people are living with cystic fibrosis in the United States, and around 1,000 new cases of cystic fibrosis are diagnosed every year.
Europe holds the second position in the malabsorption syndrome market. It is expected that the support provided by the government authorities for research & development and initiatives taken to improve the reimbursement policies in healthcare is likely to drive the European market.
Asia Pacific is the fastest growing malabsorption syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure in Australia was USD 170.4 billion, which is recorded to be 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest share of the global market due to lack of technical knowledge and poor medical facilities.
Report with Discount Available @ https://www.marketresearchfuture.com/check-discount/5460
Some of key the players in the global malabsorption syndrome market are Abbvie, Inc., Actelion Pharmaceuticals Ltd, AstraZeneca PLC, Bayer Healthcare AG, DSM, Eli Lily and Company, Gilead Sciences, GlaxoSmithKline plc, Glenmark Pharmaceuticals, KLAIRE LABORATORIES, Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, McNeil Nutritionals, National Enzyme Company, Perrigo, Pfizer, Inc., Roche, Sanofi, Vetbiochem India Private Limited, and others.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312